Halozyme Therapeutics has partnered with Pfizer to develop and commercialise products combining its Enhanze™ drug delivery platform with Pfizer biologics directed at up to 6 targets. The technology, which is based on Halozyme’s recombinant human hyaluronidase enzyme (rHuPH20), allows for improved subcutaneous delivery of small and large therapeutic molecules. Halozyme suffered a setback in August 2012 when the US FDA issued a complete response letter to partner Baxter requesting additional preclinical data for HyQ, which combines plasma-derived immune globulin 10% and rHuPH20 for subcutaneous administration in patients with primary immunodeficiency disease.